RADIOIMMUNOTHERAPY FOR HEPATIC MICROMETASTASES FROM HUMAN COLON CANCER IN CONGENITALLY ATHYMIC MICE

2001 Fiscal Year Final Research Report Summary

• Project/Area Number: 12671267
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: THE JIKEI UNIVERSITY SCHOOL OF MEDICINE
• Principal Investigator: YOSHIDA Kazuhiko Jikei University School of Medicine, Dept. of Surgery, Assistant Professor, 医学部, 助教授 (90191577)
• Co-Investigator(Kenkyū-buntansha): FIJIOKA Shuichi DEPARTMENT OF SURGERY, THE JIKEI UNIVERSITY SCHOOL OF MEDICINE, STAFF, 医学部, 助手 (80287284) ; MISAWA Takeyuki DEPARTMENT OF SURGERY, THE JIKEI UNIVERSITY SCHOOL OF MEDICINE, LECTURE, 医学部, 講師 (50260956)
• Project Period (FY): 2000 – 2001
• Keywords: monoclonal antibody / colorectal cancer / liver metastases / micrometastases

Research Abstract

To determine the efficacy of radio-labeled monoclonal antibody (mAb) for adjuvant setting in colon cancer, we performed a preclinical study using therapeutic doses of I-131 labeled mAb H-15 in a hepatic micormetastases from human colon cancer in congenitally athymic mice.
One hundred twenty mice after one week of intra-splenic injection wore given i. v. injections of either 100, μCi/1μg of I-131 labeled mAb H-15 (low dose) or 500μCi/1μg (high dose). Other 60 mice after one week of intra splenic injection were used as a control arm. The total weight of hepatic metastases of high dose I-131 labeled mAb H-15 group was statistically lower than that of either low dose group or control group. The hepatic metastases/liver and the hepatic metastases/blood ratios of high dose I-131 labeled mAb H-15 group were higher than those of low dose group. The survival rate of high dose I-131 labeled nAb H-15 group was statistically higher than either low dose group or control group.
Other one hundred eighty mice after one week of intrasplenic injection were given i. v. injections of either 500 μ Ci/1 μg of I-131 labeled nAb H-15, 5-day intra peritoneal injection of 20mg/kg of 5-FU and leucovorin (LV) (low concentration), or 5-day intra peritoneal injections of 40mg/kg of 5-FU and LV (high concentration). The total weight of hepatic motastases of I-131 labeled nAb H-15 group was significantly lower than that of either high concentration group of 5 FU/LV or low concentration group of 5 FU/LV. The survival rate of high dose I-131 labeled nAb H-15 group was statistically higher than either high concentration group of 5-FU/LV of low concentration group of 5-FU/LV.
We conclude that I-131 labeled mAb 1H-15 therapy might be an alternative to 5 FU/LV treatment in the adjuvant therapy after complete resection of colon cancer.